The Latest
New York City Makes Strides in HIV Diagnosis Times, More Work Ahead
Reducing the time between contracting HIV and being diagnosed and starting treatment is key to ending the epidemic, this study finds.
This Week in HIV Research: Where Our Reach Falls Short
Dec. 19, 2019: Often-insufficient CD4 and viral load testing for women; factors affecting syphilis incidence among women with HIV; STI testing rates among people with HIV; the effect of benzodiazepines on neurocognition.
Common Antidepressant Reduces Meth Use and High-Risk Sexual Behavior for Gay and Bisexual Men and Transgender Women
Could this give hope to people struggling with crystal meth addiction?
This Week in HIV Research: Removing Barriers to Better Care
Oct. 31, 2019: HCV treatment efficacy regardless of injection drug use; chronic pain, marijuana, and prescription opoids; the most urgent HIV training priorities; neuro effects of switching from Atripla to Complera.
Trans Women Are Increasingly A Focus of HIV Programs, But What About their Cisgender Male Partners?
This population is under-represented in HIV data, and few prevention or treatment interventions exist to support them. A new meta-analysis hopes to paint a picture of what's needed.
IDWeek 2019: What to Expect at This Year's Conference
We're covering the latest news and research from this major interdisciplinary meeting on infectious diseases, which takes place in Washington, D.C., from Oct. 2 to Oct. 6.
This Week in HIV Research: My Achy-Breaky Heart
Sep. 5, 2019: An extra decade of "heart age"; stop grouping trans women with MSM; women often have anal cancer precursor lesions; hep C treatment success doesn't equal more risk behavior.
Four PrEP Studies Address Challenges and Best Practices for Uptake and Retention
Four recent studies in JAIDS chiefly focused on PrEP provision to cisgender women and gay and bisexual men.
This Week in HIV Research: When STIs Flock Together
July 18, 2019: Anal neoplasia risk amidst comorbid HPV and chlamydia; predictive modeling for PrEP outreach; long-term benefits of hepatitis C cure in coinfection; first-line therapy with dolutegravir/lamivudine.
IAS 2019: What to Expect in HIV Science
Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.